Connection
David Camidge to Piperazines
This is a "connection" page, showing publications David Camidge has written about Piperazines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.079 |
|
|
|
-
York ER, Varella-Garcia M, Bang TJ, Aisner DL, Camidge DR. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 07; 12(7):e85-e88.
Score: 0.476
-
Noonan SA, Sachs PB, Camidge DR. Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment. J Thorac Oncol. 2016 12; 11(12):2253-2258.
Score: 0.461
-
Camidge DR. Next-generation ALK inhibitors: is the median the message? Lancet Respir Med. 2020 01; 8(1):5-7.
Score: 0.143